NTT-DATA
26.6.2024 14:01:30 CEST | Business Wire | Press release
NTT DATA, a global leader in IT infrastructure and services, today announced a strategic partnership with Zebra Technologies, a leader in digital solutions, to accelerate innovation in the 5G device ecosystem, laying the foundation for widespread adoption across industries.
Under this multi-year agreement, NTT DATA and Zebra Technologies will co-innovate to drive the adoption of 5G devices, which is essential for Private 5G adoption. Together, the two companies will enable intelligent asset tracking that allows for real-time monitoring and management of assets in industrial and enterprise deployments, ensuring enhanced visibility, efficiencies, and security capabilities critical to Industry 4.0 supply chain management.
One critical barrier to Private 5G adoption has been the availability of 5G devices for enterprises. This partnership will bridge this gap for connected devices in the enterprise Private 5G market, which Omdia estimates will grow 35% globally over the next four years, reaching nearly $10 billion by 2028.
Empowering the Private 5G Device Landscape
The agreement establishes Zebra Technologies as a strategic partner within NTT DATA’s Device as a Service practice, making it easier for customers to access, upgrade, and simplify 5G device lifecycle management and support.
Available globally, customers will benefit from continual modernization of device deployments and the ability to harness new connectivity solutions with a leading suite of Wi-Fi, Private LTE, and Private 5G compatible devices.
This news follows NTT DATA’s recent collaboration with Qualcomm, aimed to accelerate the evolution of the 5G device ecosystem. With enterprises accelerating digital transformation, more connectivity is needed to support Industry 4.0 applications and the adoption of AI at the edge.
By leveraging NTT DATA’s Private 5G leadership and Zebra Technologies' expertise in intelligent data integration, asset management, and frontline coordination, the two companies aim to make the low latency and high-security features of Private 5G enabled devices easily accessible to frontline workers in the automotive, manufacturing, healthcare, and logistics industries.
“In our relentless pursuit to drive Private 5G and Edge AI adoption within the enterprises, we’re thrilled to join forces with Zebra Technologies globally,” said Shahid Ahmed, Group Executive Vice President, Edge Services at NTT DATA. “This alliance underscores our dedication to empowering enterprises with transformative capabilities that propel edge and Private 5G use cases and data-driven experiences.”
“Our partnership with NTT DATA underscores our commitment to bring customers the latest innovations powered by Wi-Fi, Private LTE, and Private 5G networks,” said Julie Johnson, Senior Vice President and General Manager of Enterprise Mobile Computing at Zebra Technologies. “We’re excited to leverage the global scale of NTT DATA’s capabilities to benefit our customers and be a vital part of a growing 5G device ecosystem, ensuring businesses can thrive in today’s rapidly evolving landscape.”
Elevating Network Deployment
NTT DATA is deploying a Private 5G network throughout Hyster-Yale Group’s manufacturing operations. Hyster- Yale Group is also leveraging NTT DATA’s Device as a Service to gain visibility into assets and materials and improve communications within its facilities. This network will work with Zebra Technologies’, handheld mobile computers and tablets to track assets and materials as they enter and exit manufacturing sites, providing critical business intelligence, while also seamlessly connecting engineers, onsite teams, production lines, and materials storage locations. All of this comes together through a cost-effective deployment at scale efficiently managed through NTT DATA’s Device as a Service practice.
“Adding Zebra devices to our Store Front has allowed us to procure units through our Device as a Service program with NTT DATA, offering much more SKU customization within a standard device set,” said Pierluigi Mastroddi, Director of IT Infrastructure Services at Hyster-Yale Group.
Benefits of Device as a Services Model
NTT DATA’s Device as a Service offers customers a comprehensive turnkey solution for managing the entire device lifecycle. It provides expert planning, procurement, configuration, deployment, ongoing support, analytics, repair management, and device retirement, all under the stewardship of a trusted partner. This allows customers to use a cost-effective per-user, per-month program model to consume technology products on a pay-per-user subscription basis instead of purchasing/owning the equipment.
About NTT DATA
NTT DATA is a $30+ billion trusted global innovator of business and technology services. We serve 75% of the Fortune Global 100 and are committed to helping clients innovate, optimize, and transform for long-term success. We invest over $3.6 billion each year in R&D to help organizations and society move confidently and sustainably into the digital future. As a Global Top Employer, we have diverse experts in more than 50 countries and a robust partner ecosystem of established and start-up companies. Our services include business and technology consulting, data and artificial intelligence, industry solutions, as well as the development, implementation and management of applications, infrastructure, and connectivity. We are also one of the leading providers of digital and AI infrastructure in the world. NTT DATA is part of NTT Group and headquartered in Tokyo. Visit us at nttdata.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240625541170/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom